CA2458872A1 - Enzyme humain conjuguant l'ubiquitine - Google Patents

Enzyme humain conjuguant l'ubiquitine Download PDF

Info

Publication number
CA2458872A1
CA2458872A1 CA002458872A CA2458872A CA2458872A1 CA 2458872 A1 CA2458872 A1 CA 2458872A1 CA 002458872 A CA002458872 A CA 002458872A CA 2458872 A CA2458872 A CA 2458872A CA 2458872 A1 CA2458872 A1 CA 2458872A1
Authority
CA
Canada
Prior art keywords
conjugating enzyme
human ubiquitin
pharmaceutical composition
antibody
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002458872A
Other languages
English (en)
Other versions
CA2458872C (fr
Inventor
Masato Horie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP06916397A external-priority patent/JP3646191B2/ja
Application filed by Individual filed Critical Individual
Priority to CA2641565A priority Critical patent/CA2641565C/fr
Publication of CA2458872A1 publication Critical patent/CA2458872A1/fr
Application granted granted Critical
Publication of CA2458872C publication Critical patent/CA2458872C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002458872A 1996-03-19 1997-03-19 Enzyme humain conjuguant l'ubiquitine Expired - Fee Related CA2458872C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2641565A CA2641565C (fr) 1996-03-19 1997-03-19 Proteines de type nel de type 1 et de type 2 et polynucleotides les codant

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP63410/1996 1996-03-19
JP6341096 1996-03-19
JP06916397A JP3646191B2 (ja) 1996-03-19 1997-03-05 ヒト遺伝子
JP69163/1997 1997-03-05
CA002200371A CA2200371C (fr) 1996-03-19 1997-03-19 Gene humain npik

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002200371A Division CA2200371C (fr) 1996-03-19 1997-03-19 Gene humain npik

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2641565A Division CA2641565C (fr) 1996-03-19 1997-03-19 Proteines de type nel de type 1 et de type 2 et polynucleotides les codant

Publications (2)

Publication Number Publication Date
CA2458872A1 true CA2458872A1 (fr) 1997-09-19
CA2458872C CA2458872C (fr) 2009-05-19

Family

ID=32474726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458872A Expired - Fee Related CA2458872C (fr) 1996-03-19 1997-03-19 Enzyme humain conjuguant l'ubiquitine

Country Status (1)

Country Link
CA (1) CA2458872C (fr)

Also Published As

Publication number Publication date
CA2458872C (fr) 2009-05-19

Similar Documents

Publication Publication Date Title
WO1994004702A3 (fr) Procede ameliore de detection et de therapie de lesions au moyen de conjugues de biotine ou d'avidine
MXPA01011008A (es) Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata.
ATE245662T1 (de) Avidin-biotin immunokonjugate
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AP9801392A0 (en) Concentrated antibody preparation.
EP0434765A4 (en) Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
CA2124218A1 (fr) Traitement par des produits cytotoxiques
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
PT837684E (pt) Composicoes farmaceuticas a base de um sal de diclofenac e de tiocolchicosido
AU4830097A (en) Use of an extract of Cimicifuga
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
MY137303A (en) Methods for treating proliferative diseases
EP0382411A3 (fr) Délivrance d'agents cytotoxiques
ATE187890T1 (de) Ligandgerichtete enzyme-prodrug therapie
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO1999021574A3 (fr) Amelioration d'activite morphogene
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
IL135520A0 (en) 8-azabicyclo [3.2.1.] octane-3-methanamine derivatives, their preparation and their therapeutic application
AU2193797A (en) Delivery of therapeutic agents to the prostate
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
CA2458872A1 (fr) Enzyme humain conjuguant l'ubiquitine
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
WO2000014119A3 (fr) Anticorps bifonctionnels et leur utilisation dans le ciblage d'agents antitumoraux
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160321